Stock Market News1 month MRK’s Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study Zacks
The KEYLYNK-001 study evaluating Merck’s Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary goal in epithelial ovarian cancer.
XThe KEYLYNK-001 study evaluating Merck’s Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary goal in epithelial ovarian cancer.
X